Modified human IGF-IR antibodies

Details Modified human IGF-IR antibodies Modified human IGF-IR antibodies

2008-05-13

2008-05-13

Chan, Christina (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S141100, C424S143100, C530S387100, C530S388100, C530S388220

Reexamination Certificate

active

07371378

ABSTRACT:
The present invention relates to antibodies, which are directed to the human IGF-1 receptor (IGF-1R) and are to be administered for the treatment of cancer. The antibodies of the present invention have been altered to comprise antibodies with one or more selected germlne framework amino acid residues which replace one or more corresponding somatically mutated residues in the variable region of the unaltered antibody. The modification results in the framework region mutations converted to germline. The modification results in a reduced propensity for the antibody to elicit an immune response (reduced immunogenicity) following administration to a human subject.

REFERENCES:
patent: 6054561 (2000-04-01), Kucherlapati et al.
patent: 6146629 (2000-11-01), Dagan
patent: 6657103 (2003-12-01), Kucherlapati et al.
patent: 6682736 (2004-01-01), Hanson et al.
patent: 2003/0165502 (2003-09-01), Fujita-Yamaguchi
patent: 2003/0235582 (2003-12-01), Singh
patent: 2004/0086503 (2004-05-01), Cohen et al.
patent: 2004/0202655 (2004-10-01), Morton et al.
patent: WO 9109967 (1991-07-01), None
patent: WO 9317105 (1993-09-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 9633735 (1996-10-01), None
patent: WO 99060023 (1999-11-01), None
patent: WO 0056772 (2000-09-01), None
patent: WO 02053596 (2002-07-01), None
patent: WO 03059951 (2003-07-01), None
patent: WO 03093317 (2003-11-01), None
patent: WO 03100008 (2003-12-01), None
patent: WO 03100059 (2003-12-01), None
patent: WO 03106621 (2003-12-01), None
patent: WO 04071529 (2004-08-01), None
patent: WO 04087756 (2004-12-01), None
Kobrin et al, J Immunology 146: 2017-2020, 1991.
Zhu et al, Investigational New Drugs 17: 195-212, 1999.
Mitsiades, C., et al., The IGF/IGF-1R system is a major therapeutic target for multiple myeloma, other hematologic malignancies and solid tumors, Blood, vol. 100, No. 11, Nov. 16, 2004 p. 170A, XP002293672, abstract.
Mitsiades, C., et al., Gene expression and proteomic profiling of multiple myeloma (MM) cells co-cultured with bone marrow (BM) stromal cells or stimulated with BM-derived cytokines: Implications for therapeutic targeting of the BM milieu in MM, Blood, vol. 100, No. 11, Nov. 16, 2002, p. 811A, XP002293673, abstract.
Elagiab, K., et al., Immunoglobulin variable genes and epitope recognition of human monoclonal anti-Ro 52-kd in primary Sjogren's syndrome, Arthritis and Rheumatism, vol. 42, No. 11, Nov. 1999, pp. 2471-2481, XP002293674, abstract.
Aburatani, T., et al., Importance of CDR H3 basal residue in VH/VL interaction of human antibodies, Journal of Biochemistry, vol. 132, No. 5, Nov. 2002, pp. 775-782, XP002293675.
Li, S., et al., Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth, Cancer Immunol Immunother, Jul. 2000, 49: pp. 243-252, XP001113064.
Hermanto, U., et al., Inhibition of mitogen-activated protein kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced insulin-like growth factor I-mediated mitogen-activated protein kinase activation, Cell Growth & Differentiation: The Molecular Biology Journal of the American Association for Cancer Research, Dec. 2000, vol. 11, No. 12, pp. 655-664, XP002229921.
DiGiovanni, J., et al., Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice, Proc. Natl. Acad. Sci., 97: pp. 3455-3460.
Drexhage, H.A., & Wulffraat, N.M., Endocrine autoimmune disease, Netherlands Journal of Medicine, 45: pp. 285-293, (1994).
Kim, B., et al., Insulin receptor substrate 2 and shc play different roles in insulin-like growth factor I signaling, Journal of Biological Chemistry, 273 pp. 34543-34550 (1998).
Smith, L.E., et al., Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor, Nature Medicine, 5: pp. 1390-1395 (1999).
Tappy, et al, Antibodies to insulin-like growth factor I receptors in diabetes and other disorders, Diabetes, 37: pp. 1708-1714 (1998).
Thompson, K., et al., Low prevalence of autoantibodies to the insulin-like growth factor I receptor in children with short stature, Pediatric Research, 32: pp. 455-459 (1992).
Weightman, D.R., et al., Autoantibodies to IGF-1 binding sites in thyroid associated opthalmopathy, Autoimmunity, 16: pp. 251-257 (1993).
Wraight, C., et al., Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides, Nature Biotechnology, 18: pp. 521-526 (2000).
Paul, W. E., Fundamental Immunology 242 (ed., 3d ed. 1993).
Rudikoff, S., et al., Single amino acid substitution altering antigen-binding specificity, Proc Natl Acad Sci USA, vol. 79, pp. 1978—1983 (1982).
Groves, D.J., et al., Production of an Ovine Monoclonal Antibody to Testoserone by an Interspecies Fusion, Hybridoma, vol. 6, pp. 71-76 (1987).
Rubini, M, et al., Characterization of an Antibody that can Detect and Activated IGF-I Receptor in Human Cancers, Experimental Cell Research 251, pp. 22-32 (1999).
Colman, P.M., Effect of amino acid sequence changes on antibody-antigen interactions, Research in Immunology, vol. 145, pp. 33-36 (1994).

Affiliated with

Also associated with

Rating

Modified human IGF-IR antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified human IGF-IR antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified human IGF-IR antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2780758